Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Siwen Hu-LieskovanAaron LisbergJesse M ZaretskyTristan R GroganHira RizviDaniel K WellsJames CarrollAmy CummingsJohn MadrigalBenjamin JonesJacklin GukasyanI Peter ShintakuDennis SlamonSteven DubinettJonathan W GoldmanDavid ElashoffMatthew D HellmannAntoni RibasEdward B GaronPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
In patients with NSCLC treated with PD-1 blockade with long-term follow up, TMB, PD-L1, and CD8 were each associated with benefit from PD-1 blockade. Pretreatment PD-L1 expression was correlated with T lymphocyte infiltration and OS, whereas models incorporating TMB and infiltrating CD4 and CD8 lymphocytes did not substantially add to the predictive value of PD-L1 alone for OS.